Navigation Links
Clinical Pharmacology Study With AZILECT(R) (Rasagiline Tablets) Demonstrated It Does Not Increase Tyramine Sensitivity
Date:6/9/2009

in U.S. market exclusivity for certain of our new generic products and regulatory changes that may prevent us from utilizing exclusivity periods, competition from brand-name companies that are under increased pressure to counter generic products, or competitors that seek to delay the introduction of generic products, the impact of consolidation of our distributors and customers, potential liability for sales of generic products prior to a final resolution of outstanding patent litigation, including that relating to the generic versions of Neurontin(R), Lotrel(R) and Protonix(R), the effects of competition on our innovative products, especially Copaxone(R) sales, the impact of pharmaceutical industry regulation and pending legislation that could affect the pharmaceutical industry, the difficulty of predicting U.S. Food and Drug Administration, European Medicines Agency and other regulatory authority approvals, the regulatory environment and changes in the health policies and structures of various countries, our ability to achieve expected results though our innovative R&D efforts, our ability to successfully identify, consummate and integrate acquisitions, including the pending acquisition of Barr Pharmaceuticals Inc., potential exposure to product liability claims to the extent not covered by insurance, dependence on the effectiveness of our patents and other protections for innovative products, significant operations worldwide that may be adversely affected by terrorism, political or economical instability or major hostilities, supply interruptions or delays that could result from the complex manufacturing of our products and our global supply chain, environmental risks, fluctuations in currency, exchange and interest rates, and other factors that are discussed in this report and in our other filings with the U.S. Securities and Exchange Commission ("SEC").


'/>"/>
SOURCE Teva Neuroscience, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Proteolix Presents Clinical Data from Two Clinical Studies of Carfilzomib in Multiple Myeloma at the 14th Congress of the European Hematology Association
2. LNA-Based HIF-1 Alpha Inhibitor Shows Early Signs of Clinical Benefit
3. PeriCor Therapeutics Reports Positive Preclinical Results of GP531 at the European Heart Failure Congress in Nice
4. Document Management Inefficiencies Cost Clinical Study Sites Time, Money
5. ClearTrial to Chair Session at DIA 45th Annual Meeting on "Effective Operational Planning for Adaptive Clinical Trials"
6. Celsense, Inc Receives NIH Grant to Translate Cell Imaging Technology for Clinical Use
7. Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis
8. FDA Approves Labeling Change for VYVANSE(R) (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD
9. Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT-101 in Prostate, Brain, and Lung Cancers at 2009 ASCO Annual Meeting
10. Oncothyreon announces clinical data from three product candidates presented at American Society of Clinical Oncology (ASCO) Annual Meeting
11. Oral VDA CYT997 - Phase I Clinical Trial Presentation at ASCO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... , July 29, 2014  Sigma-Aldrich Corporation (NASDAQ: ... energy use, increased its investment in Green Chemistry and ... the world last year, the Company announced Monday in ... Science Changed the World? The report ... honors for being a responsible corporate citizen, including recognition ...
(Date:7/29/2014)... SPRING, Md., July 29, 2014  United Therapeutics ... announced its financial results for the second ... continued growth shows that our medicines are ... pulmonary arterial hypertension (PAH)," said Martine Rothblatt, ... Officer. "The commercial launch this quarter of ...
(Date:7/29/2014)... July 29, 2014 Eppendorf Centrifuge ... product selection. Eppendorf 5427 R is geared towards high-end ... – it is targeted towards work requiring high sample ... R as it compliments their extensive 16, 48, and ... of microcentrifuge tubes, PCR tubes, PCR strip tubes, and ...
(Date:7/29/2014)... 29, 2014 White papers by ... cloud based eClinical technologies, have been published by leading ... follow a long line of white papers by Clinovo ... Life Science Leader, Pharmaceutical Online, and OpenHealthNews. , At ... paper by CTO Marc Desgrousilliers, 'The Five Essentials ...
Breaking Biology Technology:Sigma-Aldrich Achieves Record Success in Environmental, Community Initiatives 2Sigma-Aldrich Achieves Record Success in Environmental, Community Initiatives 3United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 11United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 12United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 13International Pipette Distributor, Pipette.com Announces the Addition of the Eppendorf Centrifuge 5427 R to Their Product Portfolio 2Clinovo White Papers Published in Summer 2014 Editions of Leading Medical Device & Pharmaceutical Publications 2Clinovo White Papers Published in Summer 2014 Editions of Leading Medical Device & Pharmaceutical Publications 3
... Support Fund,s Goal of Finding a Cure for ... Animal Health and the National,Thoroughbred Racing Association (NTRA) ... the NTRA Charities - Barbaro Memorial Fund. The,partnership,s ... across the horse,industry and encourage further support of ...
... Novinski to Discuss Plans for Company in 2008 ... 31 Emisphere,Technologies, Inc. (Nasdaq: EMIS ), ... Thursday, February 7, at 10:00 AM EST. President ... the company,s,emerging business strategy. Emisphere is a biopharmaceutical ...
... Board of Directors, SAN DIEGO, Jan. 31 ... therapeutics for the,treatment of Alzheimer,s disease, announced today ... A round of financing. The financing was led ... Partners. Additional,investors included AgeChem Venture Fund, and MC ...
Cached Biology Technology:Pfizer Animal Health and NTRA Charities Team Up to Benefit the Barbaro Memorial Fund 2Emisphere to Host Business Strategy Conference Call on February 7 2Emisphere to Host Business Strategy Conference Call on February 7 3Sonexa Therapeutics, Inc., Raises $30 Million in Series A Financing to Focus on Alzheimer's Treatments 2Sonexa Therapeutics, Inc., Raises $30 Million in Series A Financing to Focus on Alzheimer's Treatments 3
(Date:7/29/2014)... has received from the National Institutes of Health ... project to support the further development of 23andMe,s ... , Specifically, the grant supports four areas ... to improve the company,s ability to identify novel ... to support the collection of a broader set ...
(Date:7/29/2014)... preterm babies latest research from the University of ... the brains of many preterm children can perform almost as ... by the University,s Robinson Research Institute has found ... injury in early life, their cognitive abilities as a teenager ... However, the results of the study, published in this month,s ...
(Date:7/29/2014)... disease it affects 1 in 100,000 people characterized ... While its cause remains unknown, a new study by a ... of Bonn in Germany and other European institutions confirms for ... study, published on 6 July in Nature Genetics , ... When we swallow, a sphincter in the lower esophagus opens, ...
Breaking Biology News(10 mins):23andMe scientists receive approximately $1.4 million in funding from National Institutes of Health 223andMe scientists receive approximately $1.4 million in funding from National Institutes of Health 3Preterm children's brains can catch up years later 2Mysterious esophagus disease is autoimmune after all 2
... Yukon River Basin provide unique insights on climate change ... local communities. The USGS coordinated interviews with ... Mary,s and Pitka,s Point, Alaska, to document their observations ... such as unpredictable weather patterns and dangerous ice conditions, ...
... unlocked a mechanism behind the way short- and long-term motor ... research from a team led by Nicolas Schweighofer of ... could potentially pave the way to more effective rehabilitation for ... motor memory is actually the product of two processes: short-term ...
... Andrea Endimiani, M.D., Ph.D., Institute of Veterinary ... by the American Society for Microbiology (ASM) to ... combining basic microbiology, epidemiology, pharmacology, biochemistry, and molecular ... traits on the outcome of infections caused by ...
Cached Biology News:Observations of climate change from indigenous Alaskans 2Observations of climate change from indigenous Alaskans 3Motor memory: The long and short of it 2The American Society for Microbiology honors Andrea Endimiani 2The American Society for Microbiology honors Andrea Endimiani 3
...
Performance, mycoplasma, virus, and endotoxin tested. Collected from calves 14 days old or less...
...
Mus musculus junctophilin 2 (Jph2) Antigen: Recombinant Protein...
Biology Products: